Mutations in the gene encoding the p110a subunit of PI3K (PIK3CA) that result in enhanced PI3K activity are frequently observed in human cancers. To better understand the role of mutant PIK3CA in the initiation or progression of tumorigenesis, we generated mice in which a PIK3CA mutation commonly detected in human cancers (the H1047R mutation) could be conditionally knocked into the endogenous Pik3ca locus. Activation of this mutation in the mouse ovary revealed that alone, Pik3ca H1047R induced premalignant hyperplasia of the ovarian surface epithelium but no tumors. Concomitantly, we analyzed several human ovarian cancers and found PIK3CA mutations coexistent with KRAS and/or PTEN mutations, raising the possibility that a secondary defect in a co-regulator of PI3K activity may be required for mutant PIK3CA to promote transformation. Consistent with this notion, we found that Pik3ca H1047R mutation plus Pten deletion in the mouse ovary led to the development of ovarian serous adenocarcinomas and granulosa cell tumors. Both mutational events were required for early, robust Akt activation. Pharmacological inhibition of PI3K/mTOR in these mice delayed tumor growth and prolonged survival. These results demonstrate that the Pik3ca H1047R mutation with loss of Pten is enough to promote ovarian cell transformation and that we have developed a model system for studying possible therapies.
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Introduction
In human cancers, somatic mutations in PIK3CA commonly target specific hot spots in the helical (E542 and E545) and kinase (H1047) domains (1, 2), resulting in enhanced lipid kinase activity and upregulation of downstream signaling events such as phosphorylation of Akt (3) . Activation of Akt is observed in up to 70% of ovarian cancers (4) due to a variety of causes, including PIK3CA mutations (8%-12%) or amplification (3%-8%) and/or PTEN loss (27%) or mutations (3-8%) (1, (5) (6) (7) (8) (9) (10) . Loss of Pten (11, 12) or overexpression of activated PI3K in the mouse ovarian surface epithelium (OSE) (13) do not lead to tumor formation; however, the ability of mutant Pik3ca to initiate tumorigenesis or drive tumor progression has not been established. Here we describe an animal model that allows us to study the effects of the Pik3ca H1047R mutation in the physiologically relevant context of a somatic, heterozygous Pik3ca mutation expressed at endogenous levels in otherwise normal cells and tissues.
Results and Discussion
We analyzed 87 human ovarian cancers for changes in PI3K pathway genes PIK3CA, PIK3R1 (encoding the PI3K p85 regulatory subunit), PTEN, and also in KRAS, which interacts with PI3K to mediate its activity (refs. 14, 15, and Supplemental Table 1 ; supplemental material available online with this article; doi:10.1172/ JCI59309DS1). We found 37% of samples exhibited genetic aberrations in one of these genes. Notably, 4 (40%) of the 10 patients who had PIK3CA mutations also exhibited PIK3R1, PTEN, and/or KRAS mutations. Analysis of 34 ovarian cancer cell lines found 3 (IGROv1, TOV21G, and MCAS) had coexisting PIK3CA mutation with PTEN and/or KRAS aberrations (Supplemental Table 1 ). Consistent with this, studies in endometrioid ovarian (11) , breast, endometrial, and colon cancers (16) have identified tumors with coexistent PIK3CA and PTEN mutations. Neither the role of endogenous levels of mutant PIK3CA nor the cooperative nature of PIK3CA and PTEN mutations has been evaluated in vivo.
To address this, we used what we believe to be a novel exon-switch strategy to generate a mutant mouse harboring a germline Pik3ca allele with a conditional H1047R mutation. We inserted loxP sites flanking exon 20 of Pik3ca and downstream placed a tandem copy of exon 20 containing a CAT→AGG change in codon 1047 ( Figure  1A and Supplemental Figures 1 and 2 ). Adenoviral Cre-mediated (AdCre-mediated) recombination leads to replacement of wildtype with mutant exon 20, resulting in p110α-H1047R protein expression at endogenous levels in otherwise normal cells, thus accurately reproducing the scenario of a naturally occurring muta-tion. The presence of the conditional allele did not affect development (Supplemental Table 2 ). Using murine embryonic fibroblasts (MEFs), we confirmed the knock-in of the Pik3ca H1047R mutation after AdCre infection in vitro (Supplemental Figures 3 and 4) . Pik3ca H1047R resulted in elevated p-Akt and p-ribosomal protein S6 (p-Rps6) levels, increased PI3K activity, enhanced proliferation, and reduced apoptosis ( Figure 1 , B-E). We have thus generated a model system in which the biological effects of Pik3ca H1047R expression can be examined both in vivo and in vitro.
Combining this mouse with a Cre-inducible knockout of Pten (17), we investigated whether two genetic hits affecting PI3K regulation (Pik3ca H1047R and Pten loss) are sufficient to promote tumorigenesis in the ovary. We induced the Pik3ca H1047R mutation and/or deleted Pten in the left ovary by intrabursal AdCre delivery, which targets recombination to the OSE, granulosa cells of the ovarian follicles, and ovarian bursal cells (refs. 11, 12, 18, 19 , and Supplemental Figure 5 ).
At 8 weeks after AdCre infection, OSE of Pik3ca H1047R mice showed mild, focal papillary serous hyperplasia, and Pik3ca H1047R Pten del/del mice showed marked hyperplasia ( Figure 2A ). p-Akt T308 and p-Akt S473 staining was strongest and located at the membrane in the OSE of double Pik3ca H1047R Pten del/del mutants ( Figure 2A H1047R mice, the hyperplasia resembled epithelial proliferation seen in the borderline (low malignant potential) subtype of human ovarian serous carcinoma. In 2 mice, we observed microinvasion of the ovarian stroma, indicating that the epithelial proliferation was neoplastic despite the absence of definitive cytological evidence of malignancy. The inability of Pik3ca H1047R to induce ovarian tumorigenesis differs from transgenic mouse models of Pik3ca H1047R inducing lung and breast (20) (21) (22) (23) tumors, but these models are driven by overexpressed Pik3ca H1047R rather than mutation of the endogenous gene, as occurs in human tumors. Possibly, the ovary could be less susceptible to transformation via a single mutation compared with other tissue types. Studies are underway to examine the role of this mutation in the lung, breast, and gastrointestinal tract. In contrast to the single mutant mice, all Pik3ca H1047R Pten del/del mice developed ovarian masses, necessitating sacrifice with a median latency of 16 weeks ( Figure 2B and Figure 3, A and B) . Macroscopic analyses at autopsy revealed that many Pik3ca H1047R Pten del/del mice developed hemorrhagic ascites, and some showed intraperitoneal masses on the peritoneal wall and diaphragm. No distant metastases were evident macroscopically. Histological examination confirmed malignancy in 15 of 18 ovarian masses, consisting of ovarian serous adenocarcinomas (Figure 3, D and E) , ovarian granulosa cell tumors (Figure 3, I-K) , and a single ovarian luteoma (Table 1) . Three mice had collision tumors composed of different histological cancer types within the same mass. Serous carcinomas exhibited high abundance and membrane localization of p-Akt S473, p-Akt T308 ( Figure 2B and Figure 3F ), cytoplasmic p-Rps6 ( Figure 3G ), and keratin ( Figure 3H ). Granulosa cell tumors were positive for inhibin ( Figure 3K) . Expression of the Pik3ca H1047R mutant and loss of PTEN protein were confirmed in tumors (Figure 2 and Supplemental Figure 7 ). Consistent with these findings, recent genomic analysis of high-grade serous ovarian cancers shows that while PIK3CA amplification and mutations are rare events in this subtype, upregulation of the pathway is seen in 45% of cases (24) .
Additionally, 13 of the 15 (86.7%) Pik3ca H1047R Pten del/del mice showed variable degrees of fibrous and/or smooth muscle hyperplasia, which formed irregular or solid masses of desmoplastic stroma or resulted in bursal wall thickening by actin-positive smooth muscle (data not shown). This phenotypic heterogeneity demonstrates that combined Pik3ca H1047R mutation and Pten loss WT or Pik3ca Lat-H1047R mice were infected with AdCre, and PI3K was immunoprecipitated using an anti-p85 antibody. PI3K activity in the immunoprecipitates was assayed using phosphatidylinositol (PI) as substrate. Phosphorylated lipids were separated by thin-layer chromatography and visualized by phosphoimager. (D) MEFs from Pik3ca WT and Pik3ca H1047R mice before or after AdCre infection were cultured and cells counted (**P < 0.05 versus WT). (E) Apoptosis was assessed using annexin V after 72 hours serum deprivation. Results are mean ± SEM; 3 independent MEF preparations.
can cooperate to potently promote proliferation or transformation in several cell types, including OSE, ovarian granulosa cells, fibroblasts, and smooth muscle cells following AdCre infection.
We compared PI3K/Akt/mTOR pathway signaling in Pik3ca H1047R Pten del/del tumor lysates with that in other mouse ovarian cancer models: Kras G12D Pten del/del and Apc S580/S580 Pten del/del (refs. 11, 12, and Figure 3L ). Pik3ca H1047R Pten del/del and Kras G12D Pten del/del tumors exhibited equivalent pathway signaling to multiple substrate proteins. While Apc S580/S580 Pten del/del tumors showed equivalent p-Pdk1 and p-Rps6 levels, they showed relatively low levels of p-Akt and its substrates. This suggests that cooperating mutations -Pten loss and Kras or Pik3ca mutation, but not Apc mutation -are required to robustly activate Akt and its direct targets.
These mutations may cooperate because both Pik3ca H1047R kinase activity and loss of PTEN's phosphatase activity are necessary to reach a threshold of PIP 3 levels required for transformation. Alternatively, since PTEN has additional, PI3K-independent tumorsuppressive functions (25) , its loss may promote tumorigenesis via these additional mechanisms. Finally, both mutations may be required to overcome negative feedback loops that could be activated as a result of only one of these genetic events.
To examine whether established Pik3ca H1047R Pten del/del tumors remained dependant on PI3K pathway activity for tumor maintenance, we utilized an ATP-competitive PI3K/mTOR inhibitor, PF04691502, currently in phase I clinical trials (26, 27) . Treatment of Pik3ca H1047R Pten del/del mice commenced 10 weeks following AdCre exposure ( Figure 3M ), and tumor progression was monitored by ultrasound (Supplemental Figure 8) . Early response was characterized by cytostasis, which significantly lengthened median survival time ( Figure 3M ), indicating a continued dependence on PI3K and/or mTOR for tumorigenesis in this model. Interestingly, tumors eventually regrew despite continuous PI3K/mTOR inhibition with PF04691502. This suggests that patients with PIK3CA H1047R mutations and loss of PTEN could be initially responsive to PI3K/mTOR inhibition, but that resistance is likely to develop. This model has the potential to provide a crucial new system for examining resistance mechanisms to PI3K pathway inhibitors and for testing novel therapeutics targeting the PI3K pathway alone or in combination with other therapies.
In summary, study of the Pik3ca H1047R mouse model described herein has demonstrated that Pik3ca mutation requires a second hit to initiate tumorigenesis in the ovary. We found that mutations in PI3K regulatory proteins co-occur in human ovarian tumors with PIK3CA mutations and demonstrate that in vivo, Pik3ca H1047R and loss of Pten is sufficient to promote ovarian cell transformation. 
Methods
Generation of Pik3ca Lat-H1047R mice. Pik3ca Lat-H1047R mice were generated by homologous recombination in embryonic stem cells (Ozgene). The targeting construct, detailed in Supplemental Figure 1 , was assembled from C57BL/6 genomic DNA and cloned into the Ozgene F_PacI_Neo vector containing a PGK-neomycin cassette flanked by FLP recombinase target (FRT) sequences. The targeting vector was electroporated into 129S1/ Sv-derived W9.5 ES cells. Targeted ES cells were injected into C57BL/6 blastocysts and chimeras crossed with C57BL/6 mice. The PGK-neomycin cassette was deleted by crossing with C57BL/6 ACTB-FLPe mice.
AdCre recombination in the ovary. Cells in the ovarian bursa were infected with AdCre, a gift from Walter Thomas (Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia) as described previously (18) ; details are provided in Supplemental Methods. Endpoints were excessive tumor burden (>1.5 cm 3 ), severe abdominal distension, or signs of severe illness (hunching, ruffled fur, or loss of responsiveness). Histology and protein analysis. Tumors were formalin fixed, and immunohistochemistry was performed as described previously (27) . For Western blotting, tumors were snap frozen and lysed in RIPA buffer. Antibodies are detailed in Supplemental Methods.
In vivo therapy. Mice received vehicle (0.5% methylcellulose) or 10 mg/kg PF04691502 orally, daily. Ovary volume was monitored by ultrasound imaging (Vevo 770, Visualsonics). Endpoints were as above or weight loss of greater than 20%. 
